To begin to test the robustness of the biomarkers we discovered on the antibody array platform, we used an independent immunoassay for CTNNB, which showed the greatest fold-change between HCC and hepatitis (Tables 4 and 5). Here, CTNNB1 is linked to hepatocellular carcinoma.